Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus, a specialty pharmaceutical company, has achieved a $2.5 million regulatory milestone under its over-the-counter license agreement with Schering-Plough Healthcare Products.
Subscribe to our email newsletter
Under the agreement, Schering-Plough is responsible for the development, manufacturing and commercialization of Zegerid branded over-the-counter (OTC) products with the dosage strength of 20mg of omeprazole for heartburn-related indications in the US and Canada.
Santarus expects to receive the $2.5 million payment within the next two weeks. Schering-Plough is seeking FDA approval to sell a Zegerid branded omeprazole/sodium bicarbonate OTC product.